Brightsurf Science News & Current Events

December 03, 2016
Moffitt Cancer Center study shows improved response rates in myelodysplastic syndromes patients treated with lenalidomide and epoetin alpha
Patients with myelodysplastic syndromes (MDS) suffer from a reduction in the number of different types of blood cells, including red blood cells leading to the development of anemia.

Study estimates global cancer cases, deaths in 2015
In 2015, there were an estimated 17.5 million cancer cases around the globe and 8.7 million deaths, according to a new report from the Global Burden of Disease Cancer Collaboration published online by JAMA Oncology.

CAR T cell immunotherapy continues to yield complete responses in leukemia
A highly innovative, personalized cell-based treatment for a high-risk form of the most common childhood cancer continues to move through clinical trials.

UH Rainbow Babies & Children's Hospital experts to present at ASH
Researchers from the Angie Fowler Adolescent & Young Adult Cancer Institute at University Hospitals Rainbow Babies & Children's Hospital will present data focused on improving clinical outcomes for pediatric hematologic disorders at the 58th Annual Meeting of the American Society of Hematology.

CPX-351 improves survival following allogeneic hematopoietic cell transplant in older high-risk acute myeloid leukemia patients
Acute myeloid leukemia, or AML, is a type of cancer of the blood and bone marrow.

Research shows patients ineligible for studies may benefit from trial participation
Patients who potentially could benefit most from participation in clinical trials due to poor prognoses often are not included based on eligibility criteria, such as existing medical illnesses.

After gene therapy, hemophilia B patients maintain near-normal levels of clotting factor
Researchers are reporting the highest and most sustained levels to date of an essential blood-clotting factor in patients with the inherited bleeding disorder hemophilia B.

CD19-targeting CAR T-cell immunotherapy yields high responses in treatment-resistant CLL
In a small, early phase trial, a high percentage of patients who had exhausted most traditional treatments for chronic lymphocytic leukemia saw their tumors shrink or even disappear after an infusion of a highly targeted, experimental CAR T-cell immunotherapy developed at Seattle's Fred Hutchinson Cancer Research Center.

Filling need for fast and accurate assessment of blood's ability to clot
Case Western Reserve University researchers have developed a portable sensor that can assess the clotting ability of a person's blood 95 times faster than current methods -- using only a single drop of blood.

Biomarker may predict which formerly treated cancer patients will develop highly fatal form of leukemia
Patients successfully treated for breast, colon and other cancers can go on to develop an often-fatal form of leukemia, sometimes years after completion of treatment, due to a genetic mutation leading to secondary malignancies known as therapy-related myeloid neoplasms (t-MNs). is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to